Literature DB >> 23675567

Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM).

Peter Valent1, Elisabeth Aberer, Christine Beham-Schmid, Christina Fellinger, Wolfgang Fuchs, Karoline V Gleixner, Rosemarie Greul, Emir Hadzijusufovic, Gregor Hoermann, Wolfgang R Sperr, Friedrich Wimazal, Stefan Wöhrl, Brigitte Zahel, Hubert Pehamberger.   

Abstract

Systemic mastocytosis (SM) is a hematopoietic neoplasm characterized by pathologic expansion of tissue mast cells in one or more extracutaneous organs. In most children and most adult patients, skin involvement is found. Childhood patients frequently suffer from cutaneous mastocytosis without systemic involvement, whereas most adult patients are diagnosed as suffering from SM. In a smaller subset of patients, SM without skin lesions develops which is a diagnostic challenge. In the current article, a diagnostic algorithm for patients with suspected SM is proposed. In adult patients with skin lesions and histologically confirmed mastocytosis in the skin (MIS), a bone marrow biopsy is recommended regardless of the serum tryptase level. In adult patients without skin lesions who are suffering from typical mediator-related symptoms, the basal serum tryptase level is an important diagnostic parameter. In those with slightly elevated tryptase (15-30 ng/ml), additional non-invasive investigations, including a KIT mutation analysis of peripheral blood cells and sonographic analysis, is performed. In adult patients in whom i) KIT D816V is detected or/and ii) the basal serum tryptase level is clearly elevated (> 30 ng/ml) or/and iii) other clinical or laboratory features are suggesting the presence of occult mastocytosis, a bone marrow biopsy should be performed. In the absence of KIT D816V and other indications of mastocytosis, no bone marrow investigation is required, but the patient's course and the serum tryptase levels are examined in the follow-up.

Entities:  

Keywords:  KIT D816V; Mastocytosis; diagnostic algorithm; staging; tryptase

Year:  2013        PMID: 23675567      PMCID: PMC3649810     

Source DB:  PubMed          Journal:  Am J Blood Res        ISSN: 2160-1992


  29 in total

Review 1.  Systemic mastocytosis.

Authors:  Cem Akin; Dean D Metcalfe
Journal:  Annu Rev Med       Date:  2004       Impact factor: 13.739

2.  Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal.

Authors:  Peter Valent; Cem Akin; Michel Arock; Knut Brockow; Joseph H Butterfield; Melody C Carter; Mariana Castells; Luis Escribano; Karin Hartmann; Philip Lieberman; Boguslaw Nedoszytko; Alberto Orfao; Lawrence B Schwartz; Karl Sotlar; Wolfgang R Sperr; Massimo Triggiani; Rudolf Valenta; Hans-Peter Horny; Dean D Metcalfe
Journal:  Int Arch Allergy Immunol       Date:  2011-10-27       Impact factor: 2.749

Review 3.  Mastocytosis: current concepts in diagnosis and treatment.

Authors:  L Escribano; C Akin; M Castells; A Orfao; D D Metcalfe
Journal:  Ann Hematol       Date:  2002-11-29       Impact factor: 3.673

Review 4.  Diagnostic value of tryptase in anaphylaxis and mastocytosis.

Authors:  Lawrence B Schwartz
Journal:  Immunol Allergy Clin North Am       Date:  2006-08       Impact factor: 3.479

5.  Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience.

Authors:  Friedrich Wimazal; Philipp Geissler; Patrik Shnawa; Wolfgang R Sperr; Peter Valent
Journal:  Int Arch Allergy Immunol       Date:  2011-11-25       Impact factor: 2.749

Review 6.  Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives.

Authors:  Michel Arock; Peter Valent
Journal:  Expert Rev Hematol       Date:  2010-08       Impact factor: 2.929

Review 7.  Diagnosis, progression patterns and prognostication in mastocytosis.

Authors:  Wolfgang R Sperr; Peter Valent
Journal:  Expert Rev Hematol       Date:  2012-06       Impact factor: 2.929

Review 8.  Mastocytosis.

Authors:  Knut Brockow; Dean D Metcalfe
Journal:  Chem Immunol Allergy       Date:  2010-06-01

Review 9.  Mast cell proliferative disorders: current view on variants recognized by the World Health Organization.

Authors:  Peter Valent; Cem Akin; Wolfgang R Sperr; Hans-Peter Horny; Dean D Metcalfe
Journal:  Hematol Oncol Clin North Am       Date:  2003-10       Impact factor: 3.722

Review 10.  Mastocytosis: state of the art.

Authors:  Hans-Peter Horny; Karl Sotlar; Peter Valent
Journal:  Pathobiology       Date:  2007       Impact factor: 4.342

View more
  2 in total

1.  [Severe therapy refractive osteoporosis : A rare differential diagnosis].

Authors:  M Gehlen; A D Lazarescu; C Hinz; N Schmidt; M Pfeifer; M Werner; H F Weidemann; M Schwarz-Eywill; A Maier
Journal:  Z Rheumatol       Date:  2016-09       Impact factor: 1.372

2.  Bullous mastocytosis in a 3-month-old infant.

Authors:  Dinesh Prasad Asati; Anurag Tiwari
Journal:  Indian Dermatol Online J       Date:  2014-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.